25 XP   0   0   10

Viking Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Viking Therapeutics Inc together

PenkeI guess you are interested in Viking Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Viking Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Viking Therapeutics Inc

I send you an email if I find something interesting about Viking Therapeutics Inc.

Quick analysis of Viking Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Viking Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.16
Expected worth in 1 year
$5.00
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$1.84
Return On Investment
2.8%

For what price can you sell your share?

Current Price per Share
$65.07
Expected price per share
$25.57 - $99.41
How sure are you?
50%

1. Valuation of Viking Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$65.07

Intrinsic Value Per Share

$-8.99 - $-10.61

Total Value Per Share

$-5.83 - $-7.44

2. Growth of Viking Therapeutics Inc (5 min.)




Is Viking Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$348.4m$161m$148.1m47.9%

How much money is Viking Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$21.2m-$16.5m-$4.6m-21.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Viking Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#158 / 1010

Most Revenue
#808 / 1010

Most Profit
#706 / 1010

Most Efficient
#248 / 1010

What can you expect buying and holding a share of Viking Therapeutics Inc? (5 min.)

Welcome investor! Viking Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Viking Therapeutics Inc.

What can you expect buying and holding a share of Viking Therapeutics Inc?

First you should know what it really means to hold a share of Viking Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Viking Therapeutics Inc is $65.07. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Viking Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Viking Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.16. Based on the TTM, the Book Value Change Per Share is $0.46 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Viking Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.22-0.3%-0.19-0.3%-0.16-0.2%-0.12-0.2%-0.09-0.1%
Usd Book Value Change Per Share-0.18-0.3%0.460.7%-0.13-0.2%0.020.0%0.080.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.18-0.3%0.460.7%-0.13-0.2%0.020.0%0.080.1%
Usd Price Per Share18.61-15.64-4.50-8.01-5.73-
Price to Earnings Ratio-20.84--20.28--6.92--18.45--17.51-
Price-to-Total Gains Ratio-103.48--81.92--57.70--96.43--83.46-
Price to Book Ratio5.89-6.88-3.21-3.74-11.79-
Price-to-Total Gains Ratio-103.48--81.92--57.70--96.43--83.46-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share65.07
Number of shares15
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.460.02
Usd Total Gains Per Share0.460.02
Gains per Quarter (15 shares)6.910.34
Gains per Year (15 shares)27.641.38
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10281801-9
20554603-8
30837404-7
4011110206-6
5013813007-5
6016615808-4
70193186010-3
80221214011-2
90249242012-1
1002762700140

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%1.039.01.02.4%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%8.031.01.020.0%8.032.01.019.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.041.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%8.031.01.020.0%8.032.01.019.5%

Fundamentals of Viking Therapeutics Inc

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-04-12 21:36:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Viking Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Viking Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Viking Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Viking Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-31,868,211.4%+31,868,211.4%
5Y-31,868,211.4%10Y-15,934,105.7%-15,934,105.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y-31,868,211.4%-449.1%-31,867,762.3%
10Y-15,934,105.7%-605.5%-15,933,500.2%
1.1.2. Return on Assets

Shows how efficient Viking Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Viking Therapeutics Inc to the Biotechnology industry mean.
  • -6.7% Return on Assets means that Viking Therapeutics Inc generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Viking Therapeutics Inc:

  • The MRQ is -6.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.7%TTM-7.4%+0.7%
TTM-7.4%YOY-9.4%+2.0%
TTM-7.4%5Y-5.7%-1.7%
5Y-5.7%10Y-46.1%+40.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.7%-13.3%+6.6%
TTM-7.4%-12.8%+5.4%
YOY-9.4%-11.7%+2.3%
5Y-5.7%-13.9%+8.2%
10Y-46.1%-15.7%-30.4%
1.1.3. Return on Equity

Shows how efficient Viking Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Viking Therapeutics Inc to the Biotechnology industry mean.
  • -7.1% Return on Equity means Viking Therapeutics Inc generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Viking Therapeutics Inc:

  • The MRQ is -7.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.1%TTM-8.0%+0.9%
TTM-8.0%YOY-10.4%+2.4%
TTM-8.0%5Y-6.2%-1.8%
5Y-6.2%10Y-22.5%+16.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.1%-16.9%+9.8%
TTM-8.0%-16.1%+8.1%
YOY-10.4%-15.1%+4.7%
5Y-6.2%-19.3%+13.1%
10Y-22.5%-20.2%-2.3%

1.2. Operating Efficiency of Viking Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Viking Therapeutics Inc is operating .

  • Measures how much profit Viking Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Viking Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Viking Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-32,384,431.9%+32,384,431.9%
5Y-32,384,431.9%10Y-16,192,216.0%-16,192,216.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y-32,384,431.9%-492.1%-32,383,939.8%
10Y-16,192,216.0%-632.4%-16,191,583.6%
1.2.2. Operating Ratio

Measures how efficient Viking Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Viking Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y323,459.776-323,459.776
5Y323,459.77610Y161,729.888+161,729.888
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y323,459.7765.739+323,454.037
10Y161,729.8887.876+161,722.012

1.3. Liquidity of Viking Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Viking Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 19.19 means the company has $19.19 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Viking Therapeutics Inc:

  • The MRQ is 19.191. The company is very able to pay all its short-term debts. +2
  • The TTM is 21.705. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ19.191TTM21.705-2.513
TTM21.705YOY12.153+9.552
TTM21.7055Y26.450-4.745
5Y26.45010Y18.691+7.759
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.1913.890+15.301
TTM21.7054.173+17.532
YOY12.1535.344+6.809
5Y26.4506.126+20.324
10Y18.6916.448+12.243
1.3.2. Quick Ratio

Measures if Viking Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Viking Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 34.94 means the company can pay off $34.94 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Viking Therapeutics Inc:

  • The MRQ is 34.943. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 39.404. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ34.943TTM39.404-4.461
TTM39.404YOY21.452+17.952
TTM39.4045Y49.489-10.085
5Y49.48910Y33.815+15.675
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ34.9433.514+31.429
TTM39.4043.998+35.406
YOY21.4525.380+16.072
5Y49.4896.105+43.384
10Y33.8156.404+27.411

1.4. Solvency of Viking Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Viking Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Viking Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.05 means that Viking Therapeutics Inc assets are financed with 5.4% credit (debt) and the remaining percentage (100% - 5.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Viking Therapeutics Inc:

  • The MRQ is 0.054. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.060. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.054TTM0.060-0.006
TTM0.060YOY0.096-0.036
TTM0.0605Y0.053+0.007
5Y0.05310Y1.331-1.278
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0540.339-0.285
TTM0.0600.336-0.276
YOY0.0960.271-0.175
5Y0.0530.366-0.313
10Y1.3310.389+0.942
1.4.2. Debt to Equity Ratio

Measures if Viking Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Viking Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 5.8% means that company has $0.06 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Viking Therapeutics Inc:

  • The MRQ is 0.058. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.065. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.058TTM0.065-0.007
TTM0.065YOY0.107-0.042
TTM0.0655Y0.057+0.008
5Y0.05710Y0.325-0.267
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0580.388-0.330
TTM0.0650.402-0.337
YOY0.1070.335-0.228
5Y0.0570.426-0.369
10Y0.3250.461-0.136

2. Market Valuation of Viking Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Viking Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Viking Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -20.84 means the investor is paying $-20.84 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Viking Therapeutics Inc:

  • The EOD is -72.870. Based on the earnings, the company is expensive. -2
  • The MRQ is -20.841. Based on the earnings, the company is expensive. -2
  • The TTM is -20.275. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-72.870MRQ-20.841-52.029
MRQ-20.841TTM-20.275-0.566
TTM-20.275YOY-6.924-13.351
TTM-20.2755Y-18.448-1.827
5Y-18.44810Y-17.507-0.941
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-72.870-2.264-70.606
MRQ-20.841-2.629-18.212
TTM-20.275-2.680-17.595
YOY-6.924-4.145-2.779
5Y-18.448-6.257-12.191
10Y-17.507-6.254-11.253
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Viking Therapeutics Inc:

  • The EOD is -101.642. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -29.070. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -25.566. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-101.642MRQ-29.070-72.573
MRQ-29.070TTM-25.566-3.504
TTM-25.566YOY-10.758-14.808
TTM-25.5665Y-25.740+0.174
5Y-25.74010Y-26.671+0.931
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-101.642-2.973-98.669
MRQ-29.070-3.333-25.737
TTM-25.566-3.553-22.013
YOY-10.758-5.605-5.153
5Y-25.740-8.376-17.364
10Y-26.671-8.865-17.806
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Viking Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.89 means the investor is paying $5.89 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Viking Therapeutics Inc:

  • The EOD is 20.584. Based on the equity, the company is expensive. -2
  • The MRQ is 5.887. Based on the equity, the company is overpriced. -1
  • The TTM is 6.879. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD20.584MRQ5.887+14.697
MRQ5.887TTM6.879-0.992
TTM6.879YOY3.213+3.666
TTM6.8795Y3.739+3.140
5Y3.73910Y11.791-8.052
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.5841.896+18.688
MRQ5.8872.115+3.772
TTM6.8792.093+4.786
YOY3.2132.884+0.329
5Y3.7393.542+0.197
10Y11.7913.916+7.875
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Viking Therapeutics Inc.

3.1. Institutions holding Viking Therapeutics Inc

Institutions are holding 72.195% of the shares of Viking Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31FMR Inc14.93140.021515004340160.0001
2023-12-31BlackRock Inc7.56890.003676058674749506.6604
2023-12-31State Street Corporation5.70510.00525732990-678072-10.5766
2023-12-31Vanguard Group Inc5.35570.00225381904975521.8461
2023-12-31Viking Global Investors LP5.12010.3507514511257179612.5029
2023-12-31AllianceBernstein L.P.3.65610.026336739351238613.489
2023-12-31Balyasny Asset Management LLC2.23260.078422435231216245.7318
2023-12-31Goldman Sachs Group Inc2.22890.003722397701645181276.6921
2023-12-31American Century Companies Inc2.2130.02852223822215940.9806
2023-12-31Geode Capital Management, LLC2.1180.004121283431015555.0106
2023-12-31Morgan Stanley - Brokerage Accounts1.50580.0025151313162244969.8845
2023-09-30Deerfield Management Co1.27280.3119127900015400013.6889
2023-12-31Wasatch Advisors Inc.1.26870.1307127494531168132.3568
2023-12-31Northern Trust Corp0.91190.0031916380-11182-1.2055
2023-12-31Deutsche Bank AG0.85550.0082859691541403170.0985
2023-12-31Charles Schwab Investment Management Inc0.77190.0037775699103791.3562
2023-12-31Bank of America Corp0.76690.00147706237834911.3176
2023-12-31Eventide Asset Management, LLC0.74640.227875000000
2023-12-31Pictet Asset Manangement SA0.69130.01436947246833556010.687
2023-12-31Massachusetts Financial Services Company0.65990.0046631556631550
Total 60.58091.231860876954+5533646+9.1%

3.2. Funds holding Viking Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Growth Compy Commingled Pl O4.38490.14834406304609581.4028
2024-02-29SPDR® S&P Biotech ETF3.86573.77963884529726001.9045
2024-01-31Fidelity Growth Company Fund3.26970.14463285633-31205-0.9408
2024-02-29Vanguard Total Stock Mkt Idx Inv3.00410.01530187621989487.0554
2024-02-29iShares Russell 2000 ETF2.32110.28822332404-381-0.0163
2023-12-31American Century US Opport. Mid Cap Gr1.91630.6537192568500
2023-12-31American Century Heritage Inv1.91630.6541192568500
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.47280.1118148002117230.1166
2024-01-31Fidelity Growth Company K61.19270.17261198475-29753-2.4224
2024-01-31AB Small Cap Growth A1.09390.71771099282-102703-8.5444
2023-09-30UBS: US Equity Small Cap Growth1.0770.5579108227010822700
2024-01-31Fidelity Series Growth Company1.0270.1676103200000
2023-12-31Fidelity Small Cap Index0.95240.0701957044123391.3061
2024-02-29iShares Russell 2000 Growth ETF0.83960.572684366732510.3868
2023-12-31Eventide Healthcare & Life Sciences I0.74640.837475000000
2024-01-31Fidelity Advisor Biotechnology I0.70221.011870558700
2023-12-31Fidelity Series Small Cap Opps0.69280.237569620000
2023-12-31Fidelity Small Cap Growth0.68380.223968717800
2024-02-29Pictet-Biotech P USD0.65033.096565349727933074.6538
2024-01-31AB Discovery Growth A0.63770.5976640764-14893-2.2715
Total 32.446714.058532604987+1532484+4.7%

3.3. Insider Transactions

Insiders are holding 5.49% of the shares of Viking Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-08Brian LianSELL26907926.87
2024-02-08Sarah Kathryn RouanSELL2500028.05
2024-01-30Brian LianSELL3500023.95
2024-01-19Sarah Kathryn RouanSELL3000023.05
2024-01-04Greg ZanteSELL1500017.9
2023-05-16Charles A Rowland JrSELL4000025
2023-05-01Brian LianSELL4500022.45
2023-04-24Lawson MacartneySELL1600022
2023-04-19Brian LianSELL3500021.45
2023-04-17Brian LianSELL15500020.45
2023-04-17Greg ZanteSELL750020
2023-04-17Lawson MacartneySELL2078620
2023-04-17Marianna ManciniSELL1250020
2023-04-13Brian LianSELL7933618.45
2023-04-11Greg ZanteSELL5629518

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Viking Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1800.461-139%-0.128-29%0.023-882%0.079-327%
Book Value Per Share--3.1612.805+13%1.461+116%2.237+41%1.305+142%
Current Ratio--19.19121.705-12%12.153+58%26.450-27%18.691+3%
Debt To Asset Ratio--0.0540.060-9%0.096-43%0.053+3%1.331-96%
Debt To Equity Ratio--0.0580.065-11%0.107-46%0.057+1%0.325-82%
Dividend Per Share----0%-0%-0%-0%
Eps---0.223-0.195-13%-0.156-30%-0.125-44%-0.092-59%
Free Cash Flow Per Share---0.160-0.166+4%-0.110-31%-0.098-39%-0.061-62%
Free Cash Flow To Equity Per Share---0.1580.449-135%-0.100-37%0.031-611%0.084-288%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---10.606--------
Intrinsic Value_10Y_min---8.989--------
Intrinsic Value_1Y_max---0.593--------
Intrinsic Value_1Y_min---0.582--------
Intrinsic Value_3Y_max---2.139--------
Intrinsic Value_3Y_min---2.035--------
Intrinsic Value_5Y_max---4.117--------
Intrinsic Value_5Y_min---3.791--------
Market Cap7171885260.000+71%2051156980.0001723258430.000+19%496256545.000+313%882983952.500+132%631950333.520+225%
Net Profit Margin----0%-0%-318682.1140%-159341.0570%
Operating Margin----0%-0%-323844.3190%-161922.1600%
Operating Ratio----0%-0%323459.776-100%161729.888-100%
Pb Ratio20.584+71%5.8876.879-14%3.213+83%3.739+57%11.791-50%
Pe Ratio-72.870-250%-20.841-20.275-3%-6.924-67%-18.448-11%-17.507-16%
Price Per Share65.070+71%18.61015.635+19%4.503+313%8.011+132%5.734+225%
Price To Free Cash Flow Ratio-101.642-250%-29.070-25.566-12%-10.758-63%-25.740-11%-26.671-8%
Price To Total Gains Ratio-361.833-250%-103.484-81.919-21%-57.699-44%-96.431-7%-83.464-19%
Quick Ratio--34.94339.404-11%21.452+63%49.489-29%33.815+3%
Return On Assets---0.067-0.074+11%-0.094+40%-0.057-14%-0.461+591%
Return On Equity---0.071-0.080+13%-0.104+47%-0.062-13%-0.225+219%
Total Gains Per Share---0.1800.461-139%-0.128-29%0.023-882%0.079-327%
Usd Book Value--348419000.000309209750.000+13%161026750.000+116%246502700.000+41%143798036.650+142%
Usd Book Value Change Per Share---0.1800.461-139%-0.128-29%0.023-882%0.079-327%
Usd Book Value Per Share--3.1612.805+13%1.461+116%2.237+41%1.305+142%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.223-0.195-13%-0.156-30%-0.125-44%-0.092-59%
Usd Free Cash Flow---17640000.000-18344000.000+4%-12099250.000-31%-10794400.000-39%-6769873.675-62%
Usd Free Cash Flow Per Share---0.160-0.166+4%-0.110-31%-0.098-39%-0.061-62%
Usd Free Cash Flow To Equity Per Share---0.1580.449-135%-0.100-37%0.031-611%0.084-288%
Usd Market Cap7171885260.000+71%2051156980.0001723258430.000+19%496256545.000+313%882983952.500+132%631950333.520+225%
Usd Price Per Share65.070+71%18.61015.635+19%4.503+313%8.011+132%5.734+225%
Usd Profit---24605000.000-21222250.000-14%-16565750.000-33%-13570800.000-45%-9351916.450-62%
Usd Revenue----0%-0%267.920-100%133.960-100%
Usd Total Gains Per Share---0.1800.461-139%-0.128-29%0.023-882%0.079-327%
 EOD+5 -3MRQTTM+16 -13YOY+14 -155Y+9 -2210Y+16 -15

4.2. Fundamental Score

Let's check the fundamental score of Viking Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-72.870
Price to Book Ratio (EOD)Between0-120.584
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than134.943
Current Ratio (MRQ)Greater than119.191
Debt to Asset Ratio (MRQ)Less than10.054
Debt to Equity Ratio (MRQ)Less than10.058
Return on Equity (MRQ)Greater than0.15-0.071
Return on Assets (MRQ)Greater than0.05-0.067
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Viking Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.921
Ma 20Greater thanMa 5071.696
Ma 50Greater thanMa 10066.503
Ma 100Greater thanMa 20043.572
OpenGreater thanClose65.750
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets368,490
Total Liabilities20,071
Total Stockholder Equity348,419
 As reported
Total Liabilities 20,071
Total Stockholder Equity+ 348,419
Total Assets = 368,490

Assets

Total Assets368,490
Total Current Assets367,225
Long-term Assets1,265
Total Current Assets
Cash And Cash Equivalents 55,516
Short-term Investments 306,563
Other Current Assets 2,522
Total Current Assets  (as reported)367,225
Total Current Assets  (calculated)364,601
+/- 2,624
Long-term Assets
Property Plant Equipment 1,126
Long-term Assets Other 139
Long-term Assets  (as reported)1,265
Long-term Assets  (calculated)1,265
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities19,135
Long-term Liabilities936
Total Stockholder Equity348,419
Total Current Liabilities
Short-term Debt 324
Accounts payable 7,512
Other Current Liabilities 11,299
Total Current Liabilities  (as reported)19,135
Total Current Liabilities  (calculated)19,135
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt936
Long-term Liabilities  (as reported)936
Long-term Liabilities  (calculated)936
+/-0
Total Stockholder Equity
Common Stock1
Retained Earnings -377,944
Accumulated Other Comprehensive Income -389
Other Stockholders Equity 726,751
Total Stockholder Equity (as reported)348,419
Total Stockholder Equity (calculated)348,419
+/-0
Other
Capital Stock1
Cash and Short Term Investments 362,079
Common Stock Shares Outstanding 100,114
Liabilities and Stockholders Equity 368,490
Net Debt -54,256
Net Invested Capital 348,419
Net Working Capital 348,090
Property Plant and Equipment Gross 1,126
Short Long Term Debt Total 1,260



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-06-302013-03-312012-12-31
> Total Assets 
0
0
0
180
277
2,014
0
3,043
2,769
22,270
19,012
15,439
12,757
18,549
16,318
14,536
15,153
14,321
11,839
22,121
78,971
144,468
306,796
302,312
300,080
294,493
290,122
284,256
277,104
271,198
263,623
256,502
250,139
237,845
224,474
210,662
195,028
181,508
166,683
168,529
150,895
400,693
382,663
368,490
368,490382,663400,693150,895168,529166,683181,508195,028210,662224,474237,845250,139256,502263,623271,198277,104284,256290,122294,493300,080302,312306,796144,46878,97122,12111,83914,32115,15314,53616,31818,54912,75715,43919,01222,2702,7693,04302,014277180000
   > Total Current Assets 
0
0
0
0
86
919
0
774
360
22,270
18,932
15,202
12,162
18,310
15,623
13,975
14,674
14,264
11,525
21,852
78,731
144,258
306,616
302,133
299,137
293,644
289,256
283,501
276,446
270,618
263,134
256,104
249,863
237,662
224,285
210,528
193,299
179,863
165,146
167,040
149,468
399,371
381,300
367,225
367,225381,300399,371149,468167,040165,146179,863193,299210,528224,285237,662249,863256,104263,134270,618276,446283,501289,256293,644299,137302,133306,616144,25878,73121,85211,52514,26414,67413,97515,62318,31012,16215,20218,93222,2703607740919860000
       Cash And Cash Equivalents 
0
0
0
180
79
891
0
756
327
9,497
2,140
769
3,959
5,160
3,055
3,076
4,359
3,394
2,568
8,988
36,356
34,610
169,506
24,779
14,343
19,123
30,952
8,377
15,260
18,790
3,870
29,117
16,805
8,829
11,264
26,371
12,454
16,226
29,408
36,632
18,362
69,519
37,185
55,516
55,51637,18569,51918,36236,63229,40816,22612,45426,37111,2648,82916,80529,1173,87018,79015,2608,37730,95219,12314,34324,779169,50634,61036,3568,9882,5683,3944,3593,0763,0555,1603,9597692,1409,497327756089179180000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
12,162
15,350
13,335
7,293
12,037
11,563
10,075
7,954
8,690
7,271
11,587
41,112
107,556
134,656
276,741
284,375
273,513
257,120
267,261
253,901
244,212
251,434
219,269
224,874
219,429
204,871
175,732
172,445
152,691
125,615
118,853
117,302
323,401
339,056
306,563
306,563339,056323,401117,302118,853125,615152,691172,445175,732204,871219,429224,874219,269251,434244,212253,901267,261257,120273,513284,375276,741134,656107,55641,11211,5877,2718,6907,95410,07511,56312,0377,29313,33515,35012,162000000000
       Other Current Assets 
0
0
0
0
8
28
0
18
33
610
1,443
1,098
910
1,114
1,005
824
2,361
2,181
1,686
1,276
1,263
2,092
2,454
613
419
1,008
1,184
7,863
7,285
7,616
7,830
7,718
8,184
9,404
8,150
8,425
8,400
10,946
10,123
3,411
3,926
960
670
2,522
2,5226709603,9263,41110,12310,9468,4008,4258,1509,4048,1847,7187,8307,6167,2857,8631,1841,0084196132,4542,0921,2631,2761,6862,1812,3618241,0051,1149101,0981,443610331802880000
   > Long-term Assets 
0
0
0
0
190
1,095
0
2,269
2,409
3,070
80
237
595
239
694
561
479
57
314
270
240
210
180
179
943
849
866
755
658
580
489
398
276
183
189
134
1,729
1,645
1,537
1,489
1,427
1,322
1,363
1,265
1,2651,3631,3221,4271,4891,5371,6451,72913418918327639848958065875586684994317918021024027031457479561694239595237803,0702,4092,26901,0951900000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
794
730
664
598
530
462
392
321
249
176
101
25
1,632
1,560
1,489
1,418
1,346
1,273
1,200
1,126
1,1261,2001,2731,3461,4181,4891,5601,63225101176249321392462530598664730794000000000000000000000000
       Other Assets 
0
0
0
0
191
0
0
2,269
2,409
0
80
237
595
239
695
561
479
57
314
269
240
210
180
179
149
119
202
157
128
118
97
398
27
7
88
109
97
85
48
71
0
0
0
0
0000714885971098872739897118128157202119149179180210240269314574795616952395952378002,4092,269001910000
> Total Liabilities 
0
0
0
431
755
25,272
0
25,172
30,608
4,876
5,742
6,714
6,987
5,764
6,098
6,493
7,607
7,733
9,613
8,657
6,339
4,105
4,743
4,562
5,506
6,139
6,630
7,137
8,821
9,251
9,830
12,158
12,916
12,871
11,353
8,778
12,758
16,278
15,398
23,207
16,830
14,578
14,423
20,071
20,07114,42314,57816,83023,20715,39816,27812,7588,77811,35312,87112,91612,1589,8309,2518,8217,1376,6306,1395,5064,5624,7434,1056,3398,6579,6137,7337,6076,4936,0985,7646,9876,7145,7424,87630,60825,172025,272755431000
   > Total Current Liabilities 
54
0
0
127
436
23,968
0
22,517
27,709
4,876
5,723
1,977
1,918
5,739
6,078
6,477
3,382
7,727
9,613
8,657
6,339
4,105
4,743
4,550
4,918
5,626
6,192
6,777
8,542
9,053
9,715
12,129
12,916
12,871
11,353
8,778
11,268
14,864
14,061
21,947
15,649
13,478
13,405
19,135
19,13513,40513,47815,64921,94714,06114,86411,2688,77811,35312,87112,91612,1299,7159,0538,5426,7776,1925,6264,9184,5504,7434,1056,3398,6579,6137,7273,3826,4776,0785,7391,9181,9775,7234,87627,70922,517023,9684361270054
       Short-term Debt 
0
0
0
0
48
292
0
304
310
1,671
1,911
2,152
0
2,383
2,826
3,270
3,270
3,050
3,180
3,451
3,721
0
0
0
281
288
295
302
309
316
323
330
279
198
115
29
150
238
299
304
309
314
319
324
324319314309304299238150291151982793303233163093022952882810003,7213,4513,1803,0503,2703,2702,8262,38302,1521,9111,6713103040292480000
       Short Long Term Debt 
0
0
0
0
0
0
0
304
0
0
0
2,152
0
0
0
3,270
0
3,050
3,180
3,451
3,721
0
0
0
281
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000002810003,7213,4513,1803,05003,2700002,1520003040000000
       Accounts payable 
54
0
0
73
379
1,416
0
1,831
1,879
1,008
402
592
1,172
1,206
881
1,204
1,727
1,305
1,555
1,530
658
1,493
1,215
959
1,676
1,870
2,095
2,431
3,098
3,209
2,756
3,988
4,848
4,210
2,852
1,444
3,119
6,104
3,142
8,529
3,799
5,611
5,711
7,512
7,5125,7115,6113,7998,5293,1426,1043,1191,4442,8524,2104,8483,9882,7563,2093,0982,4312,0951,8701,6769591,2151,4936581,5301,5551,3051,7271,2048811,2061,1725924021,0081,8791,83101,416379730054
       Other Current Liabilities 
0
0
0
7
9
80
0
59
62
1,957
2,154
1,384
746
1,287
1,351
731
1,655
894
2,030
1,398
37
2,612
3,528
3,591
2,961
3,468
3,802
4,044
5,135
5,528
6,636
7,811
7,789
8,463
8,386
7,305
7,999
8,522
10,620
13,114
11,541
7,553
7,375
11,299
11,2997,3757,55311,54113,11410,6208,5227,9997,3058,3868,4637,7897,8116,6365,5285,1354,0443,8023,4682,9613,5913,5282,612371,3982,0308941,6557311,3511,2877461,3842,1541,957625908097000
   > Long-term Liabilities 
0
0
0
0
319
1,304
0
2,655
2,900
2,679
19
4,737
5,069
25
20
16
4,224
6
4,736
4,980
4,379
1,493
1,215
12
588
513
438
360
279
198
115
29
5,127
4,408
2,967
1,473
1,490
1,414
1,337
1,260
1,181
1,100
1,018
936
9361,0181,1001,1811,2601,3371,4141,4901,4732,9674,4085,12729115198279360438513588121,2151,4934,3794,9804,73664,2241620255,0694,737192,6792,9002,65501,3043190000
       Long term Debt Total 
0
0
0
0
0
0
0
0
1,430
0
0
2,152
3,140
0
0
0
3,713
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000003,7130003,1402,152001,43000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-48
-292
0
-304
-310
-1,671
-1,911
-2,152
0
-2,383
-2,826
-3,270
-3,270
-3,050
-3,180
-3,451
-3,721
0
0
0
588
513
438
360
279
198
115
29
0
0
0
0
1,490
1,414
1,337
1,260
1,181
1,100
1,018
936
9361,0181,1001,1811,2601,3371,4141,490000029115198279360438513588000-3,721-3,451-3,180-3,050-3,270-3,270-2,826-2,3830-2,152-1,911-1,671-310-3040-292-480000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
1,470
1,957
0
2,555
1,902
0
0
731
500
0
0
0
0
0
0
0
588
513
438
360
279
198
115
29
0
0
0
0
1,490
1,414
1,337
1,260
1,181
0
0
0
0001,1811,2601,3371,4141,4900000291151982793604385135880000000500731001,9022,55501,9571,47000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
2,269
0
0
19
31
28
0
0
16
11
6
0
270
240
210
180
12
120
90
173
128
99
89
68
48
27
7
88
76
64
52
15
38
48
0
0
0
0004838155264768872748688999128173901201218021024027006111600283119002,2690000000
> Total Stockholder Equity
0
0
0
0
-479
-23,258
0
-22,129
-27,839
17,394
13,271
8,725
5,770
12,785
10,220
8,043
7,546
6,588
2,226
13,465
72,632
140,363
302,053
297,750
294,574
288,354
283,492
277,119
268,283
261,947
253,793
244,344
237,223
224,974
213,121
201,884
182,270
165,230
151,285
145,322
134,065
386,115
368,240
348,419
348,419368,240386,115134,065145,322151,285165,230182,270201,884213,121224,974237,223244,344253,793261,947268,283277,119283,492288,354294,574297,750302,053140,36372,63213,4652,2266,5887,5468,04310,22012,7855,7708,72513,27117,394-27,839-22,1290-23,258-4790000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
11111111111111111111111100000000000000000000
   Retained Earnings Total Equity000-311,580-292,049-272,490-256,717-239,285-223,182-210,826-197,583-182,202-168,192-157,244-147,956-138,384-128,697-121,247-115,516-107,842-102,918-97,678-91,078-84,406-80,855-76,770-70,671-65,499-60,277-56,633-52,825-49,132-45,545-40,454-35,718-27,85300000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
-12
-5
-7
0
-7
-6
-7
-7
-6
-4
-20
-109
-147
-117
-423
-49
239
157
12
-812
333
-46
-54
-104
-189
-170
-549
-1,411
-1,649
-1,761
-1,102
-618
-1,040
-905
-389
-389-905-1,040-618-1,102-1,761-1,649-1,411-549-170-189-104-54-46333-81212157239-49-423-117-147-109-20-4-6-7-7-6-70-7-5-12000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
14
53,124
53,730
54,278
54,902
65,617
66,858
68,327
73,053
77,264
79,000
94,339
157,146
231,587
399,847
401,090
402,464
403,630
404,581
405,803
407,478
409,569
411,082
412,589
419,528
422,745
424,116
425,614
428,086
430,390
432,330
445,267
453,057
0
0
0
000453,057445,267432,330430,390428,086425,614424,116422,745419,528412,589411,082409,569407,478405,803404,581403,630402,464401,090399,847231,587157,14694,33979,00077,26473,05368,32766,85865,61754,90254,27853,73053,1241400000000
   Treasury Stock000-6,795-6,795-6,795-6,795-5,121000000000000000000000000-8,72500000000000
   Other Stockholders Equity 
0
0
0
0
8
11
0
13
14
53,124
53,730
54,278
54,902
65,617
66,858
68,327
73,053
77,264
79,000
94,339
157,146
231,587
399,847
401,090
402,464
403,630
404,581
405,803
407,478
409,569
411,082
412,589
419,528
422,745
424,116
425,614
422,965
423,595
425,535
438,472
446,262
717,959
722,483
726,751
726,751722,483717,959446,262438,472425,535423,595422,965425,614424,116422,745419,528412,589411,082409,569407,478405,803404,581403,630402,464401,090399,847231,587157,14694,33979,00077,26473,05368,32766,85865,61754,90254,27853,73053,124141301180000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-292
Gross Profit-292-292
 
Operating Income (+$)
Gross Profit-292
Operating Expense-100,827
Operating Income-100,827-101,119
 
Operating Expense (+$)
Research Development63,806
Selling General Administrative37,021
Selling And Marketing Expenses292
Operating Expense100,827101,119
 
Net Interest Income (+$)
Interest Income11,046
Interest Expense-88
Other Finance Cost-18
Net Interest Income10,976
 
Pretax Income (+$)
Operating Income-100,827
Net Interest Income10,976
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-85,895-115,759
EBIT - interestExpense = -100,915
-85,895
-85,807
Interest Expense88
Earnings Before Interest and Taxes (EBIT)-100,827-85,807
Earnings Before Interest and Taxes (EBITDA)-100,827
 
After tax Income (+$)
Income Before Tax-85,895
Tax Provision-0
Net Income From Continuing Ops-80,849-85,895
Net Income-85,895
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses100,827
Total Other Income/Expenses Net14,932-10,976
 

Technical Analysis of Viking Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Viking Therapeutics Inc. The general trend of Viking Therapeutics Inc is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Viking Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Viking Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 89.10 < 99.41.

The bearish price targets are: 60.30 > 25.72 > 25.57.

Tweet this
Viking Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Viking Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Viking Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Viking Therapeutics Inc. The current macd is -0.90014571.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Viking Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Viking Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Viking Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Viking Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartViking Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Viking Therapeutics Inc. The current adx is 18.29.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Viking Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Viking Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Viking Therapeutics Inc. The current sar is 80.21.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Viking Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Viking Therapeutics Inc. The current rsi is 44.92. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Viking Therapeutics Inc Daily Relative Strength Index (RSI) ChartViking Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Viking Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Viking Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Viking Therapeutics Inc Daily Stochastic Oscillator ChartViking Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Viking Therapeutics Inc. The current cci is -76.1222452.

Viking Therapeutics Inc Daily Commodity Channel Index (CCI) ChartViking Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Viking Therapeutics Inc. The current cmo is -23.50430136.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Viking Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartViking Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Viking Therapeutics Inc. The current willr is -78.73488038.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Viking Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Viking Therapeutics Inc Daily Williams %R ChartViking Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Viking Therapeutics Inc.

Viking Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Viking Therapeutics Inc. The current atr is 4.69845522.

Viking Therapeutics Inc Daily Average True Range (ATR) ChartViking Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Viking Therapeutics Inc. The current obv is 346,777,379.

Viking Therapeutics Inc Daily On-Balance Volume (OBV) ChartViking Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Viking Therapeutics Inc. The current mfi is 36.60.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Viking Therapeutics Inc Daily Money Flow Index (MFI) ChartViking Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Viking Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Viking Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Viking Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.921
Ma 20Greater thanMa 5071.696
Ma 50Greater thanMa 10066.503
Ma 100Greater thanMa 20043.572
OpenGreater thanClose65.750
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Viking Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Viking Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Viking Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Viking Therapeutics Inc

I send you an email if I find something interesting about Viking Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Viking Therapeutics Inc.

Receive notifications about Viking Therapeutics Inc in your mailbox!